| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (1993) 31, 927-937
© 1993 The British Society for Antimicrobial Chemotherapy
other |
Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin
aDepartment of Infectious Diseases, University of Lund Sweden bDepartment of Microbial Diseases, The City Hospital and University of Nottingham UK cDivision of Infectious Diseases, Department of Medicine, CHUV University of Lausanne Lausanne, Switzerland
Received 9 November 1992; accepted 27 January 1993
*Correspondence to: Professor S. R. Norrby, Department of Infectious Diseases, Lund University Hospital, S-22185 Lund, Sweden
The clinical and bacteriological efficacy and safety of the antibiotics ceftazidime or imipenem/cilastatin in seriously ill patients with nosocomial infections were compared in a prospective, open, evaluator-blind, multicentre comparative trial. The study was performed in 26 European centres, the majority being intensive care units. Subjects were randomized to receive either ceftazidime 2 g bid or imipenem cilastatin 0·5 g qid given for at least five days after stratification for pneumonia, septicaemia or urinary tract infection (UTI). Three hundred and ninety-three patients with serious nosocomial infections (254 with pneumonia; 91 with septicaemia and 48 UTI were treated between February 1988 and January 1990 and their clinical and bacteriological response to antibiotic treatment assessed. There were no significant differences between ceftazidime and imipenem/cilastatin in clinical efficacy. The failure rates in evaluable patients were 22 and 26% in pneumonia, 23 and 19% in septicaemia and 0 and 5% respectively in those with UTI. Overall there was no significant difference between the two antibiotics for bacteriological response in the three infection strata. However, in patients with pneumonia ceftazidime was significantly more effective than imipenem/cilastatin in clearing patients of Pseudomonas spp.: 3/17 and 11/19 patients respectively had persistent growth of Pseudomonas spp. post-treatment (P = 0·004), and in one ceftazidime failure resistance emerged compared to six imipenem/cilastatin failures in which resistance emerged. Few drug-related adverse events were recorded in either treatment group. Monotherapy with either ceftazidime (2 g bid) or imipenem/cilastatin (0·5 g qid) is safe and effective and could be considered as an alternative to combination therapy for the treatment of serious hospital-acquired infections.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. A. El Solh and A. Alhajhusain Update on the treatment of Pseudomonas aeruginosa pneumonia J. Antimicrob. Chemother., August 1, 2009; 64(2): 229 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Masterton, A. Galloway, G. French, M. Street, J. Armstrong, E. Brown, J. Cleverley, P. Dilworth, C. Fry, A. D. Gascoigne, et al. Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy J. Antimicrob. Chemother., July 1, 2008; 62(1): 5 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. I. Siempos, K. Z. Vardakas, K. G. Manta, and M. E. Falagas Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia Eur. Respir. J., March 1, 2007; 29(3): 548 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Ambrose, R. C. Owens Jr, M. J. Garvey, and R. N. Jones Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime J. Antimicrob. Chemother., March 1, 2002; 49(3): 445 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Giamarellou Prescribing guidelines for severe Pseudomonas infections J. Antimicrob. Chemother., February 1, 2002; 49(2): 229 - 233. [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Morehead and S. J. Pinto Ventilator-Associated Pneumonia Arch Intern Med, July 10, 2000; 160(13): 1926 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Edwards and M. J. Betts Carbapenems: the pinnacle of the {beta}-lactam antibiotics or room for improvement? J. Antimicrob. Chemother., January 1, 2000; 45(1): 1 - 4. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jaccard, N. Troillet, S. Harbarth, G. Zanetti, D. Aymon, R. Schneider, R. Chiolero, B. Ricou, J. Romand, O. Huber, et al. Prospective Randomized Comparison of Imipenem-Cilastatin and Piperacillin-Tazobactam in Nosocomial Pneumonia or Peritonitis Antimicrob. Agents Chemother., November 1, 1998; 42(11): 2966 - 2972. [Abstract] [Full Text]
|
|
|
|
|
|
M. Wolff Comparison of Strategies Using Cefpirome and Ceftazidime for Empiric Treatment of Pneumonia in Intensive Care Patients Antimicrob. Agents Chemother., January 1, 1998; 42(1): 28 - 36. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. C. Polk Jr, D. H. Livingston, D. E. Fry, M. A. Malangoni, T. Fabian, L. S. Trachtenberg, S. A. Gardner, L. Kesterson, and W. G. Cheadle Treatment of Pneumonia in Mechanically Ventilated Trauma Patients: Results of a Prospective Trial Arch Surg, October 1, 1997; 132(10): 1086 - 1092. [Abstract] [PDF]
|
|